Asprosin: A risk factor for obesity and metabolic disturbance

Obesity is a major health problem worldwide. The change in nutritional behaviour is the cheif cause of obesity. The asprosin is a newly discovered hormone which is induced by fasting and stimulates glucose production from the liver. Any decrease or increase in the circulating asprosin concentration results in a consistent alteration of appetite and adiposity. Objective: The aim of the present study is to demonstrate the role of asprosin in inducing obesity and causing metabolic disturbance in terms of measuring the BMI and other biochemical parameters. Methods: this study was carried out using 20 adult and healthy male albino rats, divided into two groups: Control group (Group I) and asprosin treated group (Group II) to determine the effect of subcutaneous asprosin injection (30 μg daily for 10 days) on body weight, BMI, serum glucose, insulin, insulin resistance and lipid profile. Results: The subcutaneous asprosin injection resulted in an increase in the body weight and body mass index with a significant dyslipidemia and hyperglycemia along with insulin resistance. Conclusion: The results suggest that the hormone asprosin is responsible for the observed metabolic disturbances and increased BMI in the rats.